(RTTNews) – Today’s Daily Dose brings you news of AstraZeneca postponing its COVID-19 vaccine candidate Phase 3, Albireo’s positive knowledge of Odevixibat’s Phase 3 trial in progressive familial intrahepatic cholestasis, the disappointing effects of Corbus de their phase 3 Lenabasum trial on diffuse skin Systemic Sclerosis, RedHill’s promising “in vitro” knowledge of the COVID-19 drug candidate, tests the effects of ADAPT-PO through Spero and Pfizer’s fair investment in Trillium.
Keep reading. . .
1. AstraZeneca suspends COVID-19 vaccine trial
AstraZeneca PLC (AZN) discontinued Phase III of its COVID-19 vaccine candidate, AZD1222, following an adverse reaction in a trial participant, Stat News reports.
The United States has recorded 6,326,696 active COVID-19 cases and 189,639 deaths as of this writing, in the Johns Hopkins University database.
AZN closed Tuesday’s consultation at $54. 71, up 2. 11%. In the afternoon, inventory dropped by 8. 14% to $50. 25.
2. Albireo Pharma reaches new heights
Shares of Albireo Pharma Inc. (ALBO) rose 79% to a new 52-week high of $ 49 in intraday trading on Tuesday, following the positive effects of a phase III global clinical trial of Odevixibat on progressive familial intrahepatic cholestasis. 1 or 2, a Rare genetic liver disease.
The company plans to submit full regulatory applications for Odevixibat in the indication of progressive family intrahepathic colestase in the EU and the US. But it’s not the first time Until early 2021.
In addition, the company announced that it had entered a public tender offer for 3 million shares of its regular shares.
ALBO closed on Tuesday at $39. 62, an increase of 44. 76%.
3. Co-diagnosis to expand COVID-19 services
The Co-Diagnostics Logix Smart COVID-19 test, which is CE-marked and approved for emergency use through the FDA, is used to diagnose SARS-CoV-2, the COVID-19 virus, in the United States and many other countries.
Arches Research has conducted co-diagnostic tests for its consumers since the beginning of this year.
CODX closed Tuesday at $ 11. 70, up 41. 99%.
4. Corbus Pharma dives into disappointing results
Systemic sclerosis, a form of scleroderma, is a rare and debilitating chronic autoimmune disease that affects approximately 200,000 other people in North America, the EU and Japan.
The Combined Average Response Index of the American College of Rheumatology for Systemic Sclerosis (ACR CRISS) at week 52, which reflects the probability of patient improvement, is explained as the trial’s number one assessment criterion.
In the Phase III trial, called RESOLVE-1, there were no significant differences in the number one and secondary assessment criteria when Lenabasum was compared with a placebo, either added to fundamental immunosuppressive drugs.
The CRBP closed Tuesday’s consultation at $ 2. 23, down 75. 89%.
RedHill Opaganib is the subject of a global phase 2/3 in patients with severe COVID-19 pneumonia and phase 2 in patients with severe COVID-19 pneumonia in the United States.
RDHL closed Tuesday at $ 8. 41, an increase of 13. 04%.
6. Spero Therapeutics is based on the effects of the ADAPT-PO trial
In the phase III study, designated ADAPT-PO, oral HBr tebipenem was not statistically inferior to intravenous (IV) ertapenem approved through Merck in the treatment of patients with cUTI and patients with acute pyelonephritis.
Spero intends to complete the NDA filing for US regulatory approval. But it’s not the first time Tebipenem HBr in the quarter of 2021.
SPRO closed Tuesday’s consultation at $ 13. 07, an increase of 45. 87%. In the afternoon, the inventory 1. 07% to $ 13. 21.
7. Strongbridge Biopharma collapses even though the LOGICS study achieved the key goal
At the end of the withdrawal phase of the LOGICS study, 54. 5% more patients who were removed from placebo had an average loss of reaction in loose cortisol in urine compared to those who remained on RECORLEV, the company noted. .
Adverse occasions of specific interest on the LOGICS examination included occasions similar to liver, those similar to adrenal insufficiency, and QT interval prolongation.
The company plans to submit a request for a new RECORLEV drug to the FDA in the first quarter of 2021.
SBBP closed On Tuesday at $2. 82, down 20. 11%.
Trillium Therapeutics Inc. (TRIL) rose more than 38% after hours on Tuesday, following a plan to invest in shares of Pfizer Inc. (PFE) a registered direct offering.
The company agreed to sell 2. 29 million, which is not unusual, based on percentages at a value of $ 10. 88, which is consistent with Pfizer’s consistent percentage of gross revenue of $ 25. 0 million. The offer is expected to close around September 10, 2020.
The main applicants for Trillium come with TTI-621, in a Phase 1 study in patients with complex relapse or refractory malignancies, and TTI-622, which is being evaluated in one study. phase 1a/1b in patients with relactive or refractory complex lymphoma or myeloma.
TRIL closed Tuesday’s consultation at $9. 46, down 1. 77%. In protracted operations, inventory rose 38. 48% to $13. 10.
SCWorx Corp. (WORX) closed Tuesday’s consultation at $1. 86, up 22. 37%.
Cancer Genetics Inc. (CGIX) closed on Tuesday at $5. 26, an increase of 21. 48%.
TRACON Pharmaceuticals Inc. (TCON) closed Tuesday at $3. 74, an increase of 20. 65%.
Biocept Inc. (BIOC) closed Tuesday’s consultation at $4. 42, down 16. 89%.
Venus Concept Inc. (VERO) closed Tuesday’s consultation at $ 2. 23, down 16. 48%.